Funding for this research was provided by:
Research Councils UK (EP/E500641/1)
National Institute for Health Research
MRC-ABPI COPD-MAP consortium (G1001367/1)
Received: 21 May 2020
Accepted: 1 October 2020
First Online: 12 October 2020
Ethics approval and consent to participate
: All participants gave informed consent to this study that was approved by the NRES Committee London - Central (11/LO/1852 and 12/LO/0088).
: Not applicable.
: GH, CHW, CM, KC, and PB have no competing interest. MSP is an employee and shareholder of AstraZeneca and was previously employed by GlaxoSmithKline, neither company were involved in this work. MIP received grants and personal fees from GlaxoSmithKline during the conduct of the study and personal fees from Philips outside the submitted work. IMA received grants from MRC-ABPI during the conduct of the study. KFC received honoraria for participating in Advisory Board meetings of GlaxoSmithKline, AstraZeneca, Novartis, Merck, Boehringer Ingelheim and Teva regarding treatments for asthma and chronic obstructive pulmonary disease and has also been remunerated for speaking engagements.